Return on Invested Capital (ROIC): 3.18%
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of 3.18% is 62% below its 5-year average of 8.29%, near the low end of its 5-year range (3.18%–12.08%).
As of Saturday, June 27, 2026. 39.43% below its 12-month average of 5.25%.
TECH Return on Invested Capital (ROIC) Chart
Annual fiscal-year return on invested capital; no daily interpolation.
TECH Average Return on Invested Capital (ROIC) Chart
TECH Current vs Average Return on Invested Capital (ROIC) Chart
TECH Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
3.18%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
5.25%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
8.14%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
8.29%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
8.23%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
10.98%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
13.32%
CURRENT VS TTM AVG
-39.43%
CURRENT VS 3Y AVG
-60.95%
CURRENT VS 5Y AVG
-61.66%
CURRENT VS 10Y AVG
-61.34%
CURRENT VS 15Y AVG
-71.03%
CURRENT VS 20Y AVG
-76.13%
TECH Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio-Techne Corporation (TECH) | $11.12B | 3.18% | 5.25% | 8.14% | 8.29% |
| Insulet Corp. (PODD)vs › | $10.96B | 13.62% | 12.65% | 8.97% | 7.27% |
| Baxter International Inc. (BAX)vs › | $11.38B | -1.79% | -0.86% | -2.61% | 0.30% |
| Molina Healthcare, Inc. (MOH)vs › | $11.79B | 7.64% | 12.01% | 15.07% | 15.28% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -24.28% | -15.13% | -6.38% | -2.73% |
| Charles River Laboratories International, Inc. (CRL)vs › | $10.20B | 8.36% | 4.65% | 6.09% | 6.66% |
| Tempus AI, Inc. (TEM)vs › | $9.80B | -10.29% | -59.01% | -58.33% | -53.58% |
| Henry Schein, Inc. (HSIC)vs › | $9.68B | 6.58% | 6.66% | 7.75% | 8.24% |
| Revvity, Inc. (RVTY)vs › | $12.61B | 2.82% | 2.97% | 3.42% | 5.50% |
| Align Technology, Inc. (ALGN)vs › | $12.78B | 9.94% | 9.96% | 10.13% | 11.66% |
Capital Efficiency
ROIC
3.2%
ROE
5.3%
Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for Bio-Techne Corporation (TECH)?
- The return on invested capital (ROIC) for TECH stock is 3.18%.
- Is Bio-Techne Corporation's return on invested capital (ROIC) high or low?
- The return on invested capital (ROIC) of 3.18% is 62% below its 5-year average of 8.29%, near the low end of its 5-year range (3.18%–12.08%).
- What is the TTM average return on invested capital (ROIC) for Bio-Techne Corporation (TECH)?
- The TTM average return on invested capital (ROIC) for TECH stock is 5.25%.
- What is the 3Y average return on invested capital (ROIC) for Bio-Techne Corporation (TECH)?
- The 3Y average return on invested capital (ROIC) for TECH stock is 8.14%.
- What is the 5Y average return on invested capital (ROIC) for Bio-Techne Corporation (TECH)?
- The 5Y average return on invested capital (ROIC) for TECH stock is 8.29%.
- What is the 10Y average return on invested capital (ROIC) for Bio-Techne Corporation (TECH)?
- The 10Y average return on invested capital (ROIC) for TECH stock is 8.23%.
- What is the 15Y average return on invested capital (ROIC) for Bio-Techne Corporation (TECH)?
- The 15Y average return on invested capital (ROIC) for TECH stock is 10.98%.
- What is the 20Y average return on invested capital (ROIC) for Bio-Techne Corporation (TECH)?
- The 20Y average return on invested capital (ROIC) for TECH stock is 13.32%.
TECH Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-06-30 | 3.18% |
| 2024-06-30 | 7.32% |
| 2023-06-30 | 9.99% |
| 2022-06-30 | 12.08% |
| 2021-06-30 | 10.47% |
| 2020-06-30 | 6.72% |
| 2019-06-30 | 6.00% |
| 2018-06-30 | 8.99% |
| 2017-06-30 | 5.85% |
| 2016-06-30 | 9.89% |
| 2015-06-30 | 10.00% |
| 2014-06-30 | 13.04% |
| 2013-06-30 | 14.88% |
| 2012-06-30 | 16.84% |
| 2011-06-30 | 18.51% |
| 2010-06-30 | 21.86% |
| 2009-06-30 | 22.37% |
| 2008-06-30 | 19.94% |
| 2007-06-30 | 18.73% |
| 2006-06-30 | 20.24% |
| 2005-06-30 | 22.91% |
| 2004-06-30 | 16.84% |
| 2003-06-30 | 17.42% |
| 2002-06-30 | 16.91% |
| 2001-06-30 | 16.27% |
| 2000-06-30 | 15.73% |
| 1999-06-30 | 14.56% |
| 1998-06-30 | 21.96% |
| 1997-06-30 | 21.27% |
| 1996-06-30 | 21.13% |
Related Metrics
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kim Kelderman